{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:18:49Z","timestamp":1769221129331,"version":"3.49.0"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.micpath.2025.107625","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T19:10:59Z","timestamp":1745262659000},"page":"107625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Harnessing nanotechnology in HIV therapy: Exploring molecular pathogenesis and treatment strategies with special reference to chemotherapy and immunotherapy"],"prefix":"10.1016","volume":"204","author":[{"given":"Kaushiki","family":"Ash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhimanyu","family":"Dev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clindermatol.2024.02.001","article-title":"The global burden of HIV","volume":"42","author":"Payagala","year":"2024","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.micpath.2025.107625_bib2","series-title":"Infectious and Communicable Diseases: an Overview. Textbook of General Pathology for Dental Students","first-page":"63","author":"Prabhu","year":"2023"},{"key":"10.1016\/j.micpath.2025.107625_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijid.2019.02.016","article-title":"Epidemiological analyses of regional and age differences of HIV\/AIDS prevalence in China, 2004\u20132016","volume":"81","author":"Qiao","year":"2019","journal-title":"Int. J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib4","first-page":"1","article-title":"Nanotechnology approaches for antiretroviral drugs delivery","volume":"1","author":"Iannazzo","year":"2015","journal-title":"J. Aids. Hiv. Infec"},{"issue":"20","key":"10.1016\/j.micpath.2025.107625_bib5","doi-asserted-by":"crossref","first-page":"10798","DOI":"10.1128\/JVI.05095-11","article-title":"Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals","volume":"85","author":"Murray","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.micpath.2025.107625_bib6","first-page":"1","article-title":"HIV life cycle: overview","author":"Kirchhoff","year":"2013","journal-title":"Encyclopedia of AIDS"},{"key":"10.1016\/j.micpath.2025.107625_bib7","series-title":"Viral Infections and Antiviral Therapies","first-page":"339","article-title":"Pathophysiology of HIV and strategies to eliminate AIDS as a public health threat","author":"Sued","year":"2023"},{"issue":"9939","key":"10.1016\/j.micpath.2025.107625_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection: epidemiology, pathogenesis, treatment, and prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.micpath.2025.107625_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114217","article-title":"Natural products and synthetic analogues against HIV: a perspective to develop new potential anti-HIV drugs","volume":"233","author":"Popovi\u0107-Djordjevi\u0107","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.micpath.2025.107625_bib10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41577-021-00649-1","article-title":"Engaging innate immunity in HIV-1 cure strategies","volume":"22","author":"Board","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.micpath.2025.107625_bib11","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.tim.2019.06.002","article-title":"Molecular mechanism of HIV-1 entry","volume":"27","author":"Chen","year":"2019","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.micpath.2025.107625_bib12","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s00018-018-2772-5","article-title":"Cellular and molecular mechanisms of HIV-1 integration targeting","volume":"75","author":"Engelman","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkab324","article-title":"Long-acting antiretrovirals: a new era for the management and prevention of HIV infection","volume":"77","author":"Thoueille","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"issue":"23","key":"10.1016\/j.micpath.2025.107625_bib14","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.3390\/molecules27238502","article-title":"The use of Zidovudine pharmacophore in multi-target-directed ligands for AIDS therapy","volume":"27","author":"Bianco","year":"2022","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0000000000001660","article-title":"Twenty-five years of lamivudine: current and future use for the treatment of HIV-1 infection","volume":"78","author":"Quercia","year":"2018","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/17425250903490418","article-title":"Lamivudine for the treatment of HIV","volume":"6","author":"Kumar","year":"2010","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.micpath.2025.107625_bib17","article-title":"A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide","volume":"19","author":"Wassner","year":"2020","journal-title":"J. Int. Assoc. Phys. AIDS Care"},{"key":"10.1016\/j.micpath.2025.107625_bib18","series-title":"Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate: Is There a True Difference in Efficacy and Safety?","first-page":"72","author":"Hill","year":"2018"},{"issue":"10","key":"10.1016\/j.micpath.2025.107625_bib19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2352-4642(22)00213-9","article-title":"Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis","volume":"6","author":"Jesson","year":"2022","journal-title":"Lancet Child Adolesc. Health"},{"issue":"1\u20132","key":"10.1016\/j.micpath.2025.107625_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2008.01.002","article-title":"Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors","volume":"134","author":"Sluis-Cremer","year":"2008","journal-title":"Virus Res."},{"issue":"6","key":"10.1016\/j.micpath.2025.107625_bib21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.apsb.2019.11.010","article-title":"Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years","volume":"10","author":"Zhuang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.micpath.2025.107625_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects","volume":"191","author":"Sanne","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"326","key":"10.1016\/j.micpath.2025.107625_bib23","first-page":"2","article-title":"Influence of nevirapine on gastrointestinal function","volume":"5","author":"Umoren","year":"2015","journal-title":"J. Gastrointest. Dig. Syst."},{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jac\/dks404","article-title":"Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor","volume":"68","author":"Sharma","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.micpath.2025.107625_bib25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/COH.0000000000000474","article-title":"Rilpivirine long-acting for the prevention and treatment of HIV infection","volume":"13","author":"Ferretti","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.micpath.2025.107625_bib26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/HIV.S184018","article-title":"Doravirine and its potential in the treatment of HIV: an evidence-based review of the emerging data","author":"Rock","year":"2020","journal-title":"HIV\/AIDS - Res. Palliat. Care."},{"key":"10.1016\/j.micpath.2025.107625_bib27","doi-asserted-by":"crossref","first-page":"10576","DOI":"10.1007\/s11356-020-11267-0","article-title":"Efficacy and safety of doravirine in treatment-naive HIV-1-infected adults: a systematic review and meta-analysis","volume":"28","author":"Afify","year":"2021","journal-title":"Environ. Sci. Pollut. Control Ser."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/17425250903483207","article-title":"Efavirenz in the therapy of HIV infection","volume":"6","author":"Rakhmanina","year":"2010","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"9","key":"10.1016\/j.micpath.2025.107625_bib29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1517\/14656566.2015.1044436","article-title":"HIV integrase inhibitors: a new era in the treatment of HIV","volume":"16","author":"Blanco","year":"2015","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.micpath.2025.107625_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.JAA.0000475465.07971.19","article-title":"HIV pharmacotherapy: a review of integrase inhibitors","volume":"29","author":"Wong","year":"2016","journal-title":"Jaapa"},{"issue":"17","key":"10.1016\/j.micpath.2025.107625_bib32","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-018-1010-7","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide: a review in HIV-1 infection","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.micpath.2025.107625_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101159","article-title":"Viral proteases as therapeutic targets","volume":"88","author":"Majerov\u00e1","year":"2022","journal-title":"Mol. Aspect. Med."},{"issue":"6","key":"10.1016\/j.micpath.2025.107625_bib34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1517\/14656566.8.6.839","article-title":"Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients","volume":"8","author":"de Mendoza","year":"2007","journal-title":"Expet Opin. Pharmacother."},{"issue":"1\u20132","key":"10.1016\/j.micpath.2025.107625_bib35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000339862","article-title":"Darunavir: a critical review of its properties, use and drug interactions","volume":"90","author":"Ruela Correa","year":"2012","journal-title":"Pharmacology"},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12981-023-00506-2","article-title":"Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study","volume":"20","author":"Srichatrapimuk","year":"2023","journal-title":"AIDS Res. Ther."},{"issue":"5","key":"10.1016\/j.micpath.2025.107625_bib37","first-page":"1023","article-title":"Lopinavir\/ritonavir in the treatment of HIV-1 infection: a review","volume":"4","author":"Chandwani","year":"2008","journal-title":"Therapeut. Clin. Risk Manag."},{"issue":"11","key":"10.1016\/j.micpath.2025.107625_bib38","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/17425255.2019.1685495","article-title":"Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV","volume":"15","author":"Cattaneo","year":"2019","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3947\/ic.2020.0100","article-title":"An overview of human immunodeficiency virus-1 antiretroviral drugs: general principles and current status","volume":"53","author":"Shin","year":"2021","journal-title":"Infect Chemother"},{"key":"10.1016\/j.micpath.2025.107625_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106366","article-title":"In-vitro dynamic dissolution\/bioconversion\/permeation of fosamprenavir using a novel tool with an artificial biomimetic permeation barrier and microdialysis-sampling","volume":"181","author":"Eriksen","year":"2023","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.micpath.2025.107625_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115847","article-title":"Synthetic approaches and application of clinically approved small-molecule anti-HIV drugs: an update","author":"Sun","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"33","key":"10.1016\/j.micpath.2025.107625_bib42","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.2174\/138161210794079218","article-title":"Inhibition of HIV-1 by fusion inhibitors","volume":"16","author":"Eggink","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.micpath.2025.107625_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1517\/14656566.6.3.453","article-title":"Enfuvirtide: the first HIV fusion inhibitor","volume":"6","author":"Lazzarin","year":"2005","journal-title":"Expet Opin. Pharmacother."},{"issue":"16","key":"10.1016\/j.micpath.2025.107625_bib44","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1517\/14656566.2010.522178","article-title":"Enfuvirtide: from basic investigations to current clinical use","volume":"11","author":"Joly","year":"2010","journal-title":"Expet Opin. Pharmacother."},{"issue":"7","key":"10.1016\/j.micpath.2025.107625_bib45","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0149-2918(08)80048-3","article-title":"Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection","volume":"30","author":"Lieberman-Blum","year":"2008","journal-title":"Clin. Ther."},{"issue":"13","key":"10.1016\/j.micpath.2025.107625_bib46","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1016\/S0968-0896(03)00161-5","article-title":"Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors","volume":"11","author":"Kazmierski","year":"2003","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2710.2008.00978.x","article-title":"The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies","volume":"34","author":"Dhami","year":"2009","journal-title":"J. Clin. Pharm. Therapeut."},{"issue":"19","key":"10.1016\/j.micpath.2025.107625_bib48","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.107625_bib49","series-title":"Antiretroviral Therapy and Neurocognitive Functions in People Living with HIV","author":"Amusan","year":"2021"},{"key":"10.1016\/j.micpath.2025.107625_bib50","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2147\/PPA.S413192","article-title":"Quality of life and associated factors of HIV patients under treatment with first line regimens in public hospitals in Amhara region, north-west Ethiopia","author":"Tegegne","year":"2023","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.micpath.2025.107625_bib51","series-title":"Transforming HIV-1 Management the Revolutionary Impact of CART","author":"Thomos","year":"2023"},{"key":"10.1016\/j.micpath.2025.107625_bib52","series-title":"HIV-1 Fitness: Implications for Drug Resistance, Disease Progression, and Global Epidemic Evolution. HIV Sequence Compendium, 2001","first-page":"134","author":"Qui\u00f1ones-Mateu","year":"2001"},{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib53","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1021\/np034016p","article-title":"Plant substances as anti-HIV agents selected according to their putative mechanism of action","volume":"67","author":"Cos","year":"2004","journal-title":"J. Nat. Prod."},{"issue":"14","key":"10.1016\/j.micpath.2025.107625_bib54","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2174\/138955710793564133","article-title":"Inhibitors from natural products to HIV-1 reverse transcriptase, protease and integrase","volume":"10","author":"Jiang","year":"2010","journal-title":"Mini Rev. Med. Chem."},{"issue":"3","key":"10.1016\/j.micpath.2025.107625_bib55","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/med.21484","article-title":"Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives","volume":"38","author":"Xiao","year":"2018","journal-title":"Med. Res. Rev."},{"issue":"6","key":"10.1016\/j.micpath.2025.107625_bib56","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1055\/s-1999-14004","article-title":"HIV reverse transcriptase inhibitors of natural origin","volume":"65","author":"Matth\u00e9e","year":"1999","journal-title":"Planta Med."},{"issue":"4","key":"10.1016\/j.micpath.2025.107625_bib57","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bjp.2018.10.006","article-title":"Chemical diversity and activity profiles of HIV-1 reverse transcriptase inhibitors from plants","volume":"29","author":"Chinsembu","year":"2019","journal-title":"Revista Brasileira de Farmacognosia"},{"issue":"4","key":"10.1016\/j.micpath.2025.107625_bib58","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1248\/bpb.27.544","article-title":"Inhibition of HIV-1 reverse transcriptase and protease by phlorotannins from the brown alga Ecklonia cava","volume":"27","author":"Ahn","year":"2004","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.micpath.2025.107625_bib59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-12-387669-0.00020-X","article-title":"Anti-HIV activity of extracts and compounds from marine algae","volume":"64","author":"Kim","year":"2011","journal-title":"Adv. Food Nutr. Res."},{"key":"10.1016\/j.micpath.2025.107625_bib60","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1590\/S0102-695X2012005000084","article-title":"HIV-1 Reverse Transcriptase: a potential target for marine products","volume":"22","author":"Miceli","year":"2012","journal-title":"Revista Brasileira de Farmacognosia"},{"key":"10.1016\/j.micpath.2025.107625_bib61","series-title":"Sustainable Global Resources of Seaweeds Volume 2: Food, Pharmaceutical and Health Applications","first-page":"455","article-title":"Antiviral applications of macroalgae","author":"Singh","year":"2022"},{"issue":"7","key":"10.1016\/j.micpath.2025.107625_bib62","first-page":"953","article-title":"Marine natural products with anti-HIV activities in the last decade","volume":"20","author":"Zhou","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.micpath.2025.107625_bib63","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/B978-0-12-817907-9.00009-X","article-title":"Natural products from plants with prospective anti-HIV activity and relevant mechanisms of action","volume":"66","author":"Mandal","year":"2020","journal-title":"Stud. Nat. Prod. Chem."},{"issue":"6","key":"10.1016\/j.micpath.2025.107625_bib64","first-page":"693","article-title":"Anti-HIV-1 integrase activity of Thai medicinal plants in longevity preparations","volume":"33","author":"Bunluepuech","year":"2011","journal-title":"Songklanakarin J. Sci. Technol."},{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib65","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0378-1119(95)00186-A","article-title":"Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon","volume":"161","author":"Lee-Huang","year":"1995","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/cmdc.200700223","article-title":"Hyrtiosal, from the marine sponge Hyrtios erectus, inhibits HIV\u20101 integrase binding to viral DNA by a new inhibitor binding site","volume":"3","author":"Du","year":"2008","journal-title":"ChemMedChem: Chemistry Enabling Drug Discovery"},{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib67","first-page":"116","article-title":"Survey of anti-HIV and anti-HCV compounds from Natural sources","volume":"1","author":"Hattori","year":"2013","journal-title":"Can. Chem. Trans."},{"issue":"13","key":"10.1016\/j.micpath.2025.107625_bib68","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.2174\/1568026033451790","article-title":"Natural products with anti-HIV activity from marine organisms","volume":"3","author":"Tziveleka","year":"2003","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.micpath.2025.107625_bib69","series-title":"Depth Matters:(anti) Microbial Diversity of Marine Sponges","author":"Indraningrat","year":"2019"},{"issue":"6","key":"10.1016\/j.micpath.2025.107625_bib70","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/md18060307","article-title":"Secondary metabolites of the genus Didemnum: a comprehensive review of chemical diversity and pharmacological properties","volume":"18","author":"Youssef","year":"2020","journal-title":"Mar. Drugs"},{"issue":"5","key":"10.1016\/j.micpath.2025.107625_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.201700560","article-title":"Terpenes from Euphorbia antiquorum and their in vitro anti\u2010HIV activity","volume":"15","author":"Dong","year":"2018","journal-title":"Chem. Biodivers."},{"issue":"143","key":"10.1016\/j.micpath.2025.107625_bib72","first-page":"2167","article-title":"Phytochemical analysis of Cynanchum callialatum through GCMS and LCMS","volume":"3","author":"Karthikeyan","year":"2014","journal-title":"J. Homeopathy Ayurvedic Med."},{"key":"10.1016\/j.micpath.2025.107625_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-4-41","article-title":"Punica granatum (Pomegranate) juice provides an HIV-1 entry inhibitor and candidate topical microbicide","volume":"4","author":"Neurath","year":"2004","journal-title":"BMC Infect. Dis."},{"issue":"12","key":"10.1016\/j.micpath.2025.107625_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014360","article-title":"Grifonin-1: a small HIV-1 entry inhibitor derived from the algal lectin, Griffithsin","volume":"5","author":"Micewicz","year":"2010","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.micpath.2025.107625_bib75","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1021\/jo020120k","article-title":"Unusual sulfamate indoles and a novel indolo [3, 2-a] carbazole from Ancorina sp","volume":"67","author":"Meragelman","year":"2002","journal-title":"J. Org. Chem."},{"issue":"5","key":"10.1016\/j.micpath.2025.107625_bib76","first-page":"5","article-title":"Research progress on the prevention and treatment of AIDS with traditional Chinese medicine","volume":"4","author":"Yue","year":"2022","journal-title":"differentiation"},{"issue":"6","key":"10.1016\/j.micpath.2025.107625_bib77","doi-asserted-by":"crossref","first-page":"50","DOI":"10.53388\/TMR20220214001","article-title":"Role of traditional Chinese medicine in incomplete immune reconstitution of HIV. AIDS: a review","volume":"7","author":"Ji","year":"2022","journal-title":"Tradit. Med. Res"},{"key":"10.1016\/j.micpath.2025.107625_bib78","article-title":"Anti-HIV activity in traditional Chinese medicine: clinical implications of monomeric herbal remedies and compound decoctions","volume":"11","author":"Zhang","year":"2024","journal-title":"Front. Med."},{"issue":"5","key":"10.1016\/j.micpath.2025.107625_bib79","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3390\/ijms19051459","article-title":"Medicinal plants used in the treatment of human immunodeficiency virus","volume":"19","author":"Salehi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.micpath.2025.107625_bib80","series-title":"AIDS Updates-Recent Advances and New Perspectives","article-title":"Nanotechnology based drug delivery for HIV-AIDS treatment","author":"Sailaja","year":"2021"},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/17425247.2017.1360863","article-title":"Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections","volume":"15","author":"Lembo","year":"2018","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.micpath.2025.107625_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1423-0127-17-57","article-title":"Development of a liposomal nanodelivery system for nevirapine","volume":"17","author":"Ramana","year":"2010","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.micpath.2025.107625_bib83","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2018.04.014","article-title":"Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy","volume":"138","author":"Gao","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10611860500525370","article-title":"Reduced hematopoietic toxicity, enhanced cellular uptake and altered pharmacokinetics of azidothymidine loaded galactosylated liposomes","volume":"14","author":"Garg","year":"2006","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib85","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/cryst11010033","article-title":"Top-down synthesis of a lamivudine-zidovudine nano co-crystal","volume":"11","author":"Witika","year":"2020","journal-title":"Crystals"},{"issue":"3","key":"10.1016\/j.micpath.2025.107625_bib86","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jconrel.2006.09.016","article-title":"Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages","volume":"116","author":"Hillaireau","year":"2006","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.micpath.2025.107625_bib87","first-page":"117","article-title":"Synthesis, characterization and hepatoprotective activity of Neem gold nanoparticles for improved efficacy and sustained drug release profile of Azidothymidine","volume":"26","author":"Kesarkar","year":"2014","journal-title":"Int. J. Pharm. Sci. Rev. Res"},{"key":"10.1016\/j.micpath.2025.107625_bib88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13404-017-0213-0","article-title":"Engineering of pectin-reduced gold nanoparticles for targeted delivery of an antiviral drug to macrophages: in vitro and in vivo assessment","volume":"50","author":"Borker","year":"2017","journal-title":"Gold Bull."},{"key":"10.1016\/j.micpath.2025.107625_bib89","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.colcom.2018.10.004","article-title":"Design of antiretroviral drug-polymeric nanoparticles laden buccal films for chronic HIV therapy in paediatrics","volume":"27","author":"Sneha","year":"2018","journal-title":"Colloid and Interface Science Communications"},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib90","article-title":"Enhancement of liver targetability through statistical optimization and surface modification of biodegradable nanocapsules loaded with lamivudine","volume":"2023","author":"Grandhi","year":"2023","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.micpath.2025.107625_bib91","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bbagen.2006.12.007","article-title":"Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer","volume":"1770","author":"Dutta","year":"2007","journal-title":"Biochim. Biophys. Acta (BBA) Gen. Subj."},{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib92","article-title":"Prolonged drug delivery system of PEGylated PAMAM dendrimers with a anti-HIV drug","volume":"3","author":"Kumar","year":"2015","journal-title":"Res. Pharm."},{"key":"10.1016\/j.micpath.2025.107625_bib93","article-title":"Synthesis and characterization of a conjugate of silver nanoparticles loaded with tenofovir disoproxil fumarate","volume":"5","author":"Olojede","year":"2024","journal-title":"Nanotechnology"},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib94","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/21691401.2022.2042009","article-title":"Evaluation of tenofovir disoproxil fumarate loaded silver nanoparticle on testicular morphology in experimental type-2 diabetic rats","volume":"50","author":"Olojede","year":"2022","journal-title":"Artif. Cell Nanomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib95","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12951-022-01750-w","article-title":"Tenofovir-tethered gold nanoparticles as a novel multifunctional long-acting anti-HIV therapy to overcome deficient drug delivery-: an in vivo proof of concept","volume":"21","author":"Fotooh Abadi","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.micpath.2025.107625_bib96","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jconrel.2021.05.003","article-title":"Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis","volume":"334","author":"Nunes","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.micpath.2025.107625_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119441","article-title":"Synthesis of a long acting nanoformulated emtricitabine ProTide","volume":"222","author":"Soni","year":"2019","journal-title":"Biomaterials"},{"issue":"15","key":"10.1016\/j.micpath.2025.107625_bib98","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2217\/nnm-2016-0164","article-title":"Development and characterization of a long-acting nanoformulated abacavir prodrug","volume":"11","author":"Singh","year":"2016","journal-title":"Nanomedicine"},{"issue":"4","key":"10.1016\/j.micpath.2025.107625_bib99","first-page":"43","article-title":"Formulation development and in-vitro assessment of rilpivirine nanobilosomes","volume":"19","author":"Rawat","year":"2024","journal-title":"Biochim. Biophys. Acta (BBA) Gen. Subj."},{"key":"10.1016\/j.micpath.2025.107625_bib100","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1208\/s12249-018-1064-6","article-title":"Investigation of cyclodextrin-based nanosponges for solubility and bioavailability enhancement of rilpivirine","volume":"19","author":"Rao","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.micpath.2025.107625_bib101","article-title":"Non-nuke HIV-1 inhibitor shuttled by mesoporous silica nanoparticles effectively slows down HIV-1 replication in infected human cells","volume":"194","author":"Abadi","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib102","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijpharm.2011.09.041","article-title":"Surface modified nevirapine nanosuspensions for viral reservoir targeting: in vitro and in vivo evaluation","volume":"421","author":"Shegokar","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.micpath.2025.107625_bib103","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1208\/s12249-022-02377-8","article-title":"Mannose-anchored nano-selenium loaded nanostructured lipid carriers of etravirine for delivery to HIV reservoirs","volume":"23","author":"Rojekar","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.micpath.2025.107625_bib104","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-97902022e18800","article-title":"Efavirenz dissolution enhancement V-A combined top down\/bottom up approach on nanocrystals formulation","volume":"58","author":"Sartori","year":"2022","journal-title":"Braz. J. Pharm. Sci."},{"key":"10.1016\/j.micpath.2025.107625_bib105","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.msec.2016.05.064","article-title":"Engineered nanoparticles of Efavirenz using methacrylate co-polymer (Eudragit-E100) and its biological effects in-vivo","volume":"67","author":"Hari","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.micpath.2025.107625_bib106","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.biomaterials.2017.08.029","article-title":"Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir","volume":"144","author":"Mohideen","year":"2017","journal-title":"Biomaterials"},{"issue":"9","key":"10.1016\/j.micpath.2025.107625_bib107","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4314\/tjpr.v14i9.2","article-title":"Preparation, characterization and evaluation of elvitegravir-loaded solid lipid nanoparticles for enhanced solubility and dissolution rate","volume":"14","author":"Kommavarapu","year":"2015","journal-title":"Trop. J. Pharmaceut. Res."},{"key":"10.1016\/j.micpath.2025.107625_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125166","article-title":"PEGylated solid lipid nanoparticles for the intranasal delivery of combination antiretroviral therapy composed of Atazanavir and Elvitegravir to treat NeuroAIDS","volume":"670","author":"Bazargani","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.micpath.2025.107625_bib109","first-page":"1798","article-title":"Preparation, optimization, and evaluation of dolutegravir nanosuspension: in vitro and in vivo characterization","volume":"18","author":"Bhairam","year":"2023","journal-title":"Biochim. Biophys. Acta (BBA) Gen. Subj."},{"issue":"4","key":"10.1016\/j.micpath.2025.107625_bib110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.35333\/jrp.2020.203","article-title":"Dolutegravir sodium loaded solid lipid nanoparticles: a vaginal drug delivery system for pre-exposure prophylaxis of HIV","volume":"24","author":"Anjum","year":"2020","journal-title":"J. Res. Pharm"},{"key":"10.1016\/j.micpath.2025.107625_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122226","article-title":"Anti-CD4 antibody and dendrimeric peptide based targeted nano-liposomal dual drug formulation for the treatment of HIV infection","volume":"334","author":"Mutalik","year":"2023","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.micpath.2025.107625_bib112","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/jphp.12737","article-title":"Encapsulation of ritonavir in solid lipid nanoparticles: in-vitro anti-HIV-1 activity using lentiviral particles","volume":"69","author":"Javan","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"issue":"7","key":"10.1016\/j.micpath.2025.107625_bib113","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jphp.12716","article-title":"Comparative pharmacokinetic evaluation of lopinavir and lopinavir-loaded solid lipid nanoparticles in hepatic impaired rat model","volume":"69","author":"Ravi","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"issue":"4","key":"10.1016\/j.micpath.2025.107625_bib114","first-page":"12037","article-title":"Design, formulation, in-vitro and ex-vivo evaluation of atazanavir loaded cubosomal gel","volume":"11","author":"Chettupalli","year":"2021","journal-title":"Biointerface Res. Appl. Chem"},{"issue":"7","key":"10.1016\/j.micpath.2025.107625_bib115","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1007\/s13346-023-01492-8","article-title":"Antiretroviral action of Rosemary oil-based atazanavir formulation and the role of self-nanoemulsifying drug delivery system in the management of HIV-1 infection","volume":"14","author":"Kumar","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"issue":"1\u20132","key":"10.1016\/j.micpath.2025.107625_bib116","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijpharm.2012.04.054","article-title":"Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity","volume":"431","author":"Ramana","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.micpath.2025.107625_bib117","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/jps.24046","article-title":"Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles","volume":"103","author":"Duan","year":"2014","journal-title":"J. Pharmaceut. Sci."},{"issue":"9","key":"10.1016\/j.micpath.2025.107625_bib118","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/aps.2015.53","article-title":"Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation","volume":"36","author":"He","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.micpath.2025.107625_bib119","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejpb.2018.04.009","article-title":"Towards a Maraviroc long-acting injectable nanoformulation","volume":"138","author":"Tatham","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib120","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-030409-101256","article-title":"The role of antibodies in HIV vaccines","volume":"28","author":"Mascola","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"21\u201322","key":"10.1016\/j.micpath.2025.107625_bib121","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.drudis.2011.08.013","article-title":"HIV vaccine: hopes and hurdles","volume":"16","author":"Chhatbar","year":"2011","journal-title":"Drug Discov. Today"},{"issue":"26","key":"10.1016\/j.micpath.2025.107625_bib122","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1016\/j.vaccine.2016.02.074","article-title":"Status of vaccine research and development of vaccines for HIV-1","volume":"34","author":"Safrit","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib123","article-title":"HIV vaccine research: the challenge and the way forward","volume":"2015","author":"Wang","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.micpath.2025.107625_bib124","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.coviro.2018.02.004","article-title":"Fundamental challenges to the development of a preventive HIV vaccine","volume":"29","author":"Rios","year":"2018","journal-title":"Curr Opin Virol."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib125","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev-biophys-060414-034156","article-title":"Structure and immune recognition of the HIV glycan shield","volume":"47","author":"Crispin","year":"2018","journal-title":"Annu. Rev. Biophys."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib126","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.immunol.24.021605.090605","article-title":"HIV vaccines","volume":"24","author":"McMichael","year":"2006","journal-title":"Annu. Rev. Immunol."},{"issue":"15","key":"10.1016\/j.micpath.2025.107625_bib127","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0264-410X(02)00074-9","article-title":"HIV vaccine strategies","volume":"20","author":"Nabel","year":"2002","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.micpath.2025.107625_bib128","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00948-23","article-title":"HIV-1 reverse transcriptase stability correlates with Gag cleavage efficiency: reverse transcriptase interaction implications for modulating protease activation","volume":"97","author":"Hsieh","year":"2023","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.micpath.2025.107625_bib129","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14760584.2019.1690458","article-title":"Strategies for inducing effective neutralizing antibody responses against HIV-1","volume":"18","author":"del Moral-S\u00e1nchez","year":"2019","journal-title":"Expet Rev. Vaccine"},{"issue":"5","key":"10.1016\/j.micpath.2025.107625_bib130","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.micpath.2025.107625_bib131","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1002\/eji.201545513","article-title":"Toward a cure for HIV\u2014seeking effective therapeutic vaccine strategies","volume":"45","author":"Autran","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"8","key":"10.1016\/j.micpath.2025.107625_bib132","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14760584.2019.1640117","article-title":"Novel prime-boost vaccine strategies against HIV-1","volume":"18","author":"Excler","year":"2019","journal-title":"Expet Rev. Vaccine"},{"key":"10.1016\/j.micpath.2025.107625_bib133","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fimmu.2014.00417","article-title":"Challenges in HIV vaccine research for treatment and prevention","volume":"5","author":"Ensoli","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2025.107625_bib134","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3389\/fimmu.2017.02009","article-title":"Development of a preventive HIV vaccine requires solving inverse problems which is unattainable by rational vaccine design","volume":"8","author":"Van Regenmortel","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2025.107625_bib135","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.coviro.2016.02.010","article-title":"Approaches to preventative and therapeutic HIV vaccines","volume":"17","author":"Gray","year":"2016","journal-title":"Curr Opin Virol."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib136","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S2055-6640(20)30695-6","article-title":"HIV-1 prophylactic vaccines: state of the art","volume":"2","author":"Leli\u00e8vre","year":"2016","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.micpath.2025.107625_bib137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4690-10-72","article-title":"Development of prophylactic vaccines against HIV-1","volume":"10","author":"Schiffner","year":"2013","journal-title":"Retrovirology"},{"issue":"4","key":"10.1016\/j.micpath.2025.107625_bib138","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.it.2023.02.001","article-title":"Programming cytomegalovirus as an HIV vaccine","volume":"44","author":"Picker","year":"2023","journal-title":"Trends Immunol."},{"key":"10.1016\/j.micpath.2025.107625_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2015.05.001","article-title":"HIV therapeutic vaccines: moving towards a functional cure","volume":"35","author":"Mylvaganam","year":"2015","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/QAI.0000000000000926","article-title":"Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: a randomized, double-blind, placebo-controlled clinical trial","volume":"72","author":"Jacobson","year":"2016","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"issue":"12","key":"10.1016\/j.micpath.2025.107625_bib141","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.3390\/ijms17121985","article-title":"Dendritic cell-based immunotherapies to fight HIV: how far from a success story? A systematic review and meta-analysis","volume":"17","author":"Coelho","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.micpath.2025.107625_bib142","first-page":"1","article-title":"Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies\/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I\/II randomized controlled clinical trial","volume":"13","author":"Loret","year":"2016","journal-title":"Retrovirology"},{"issue":"10","key":"10.1016\/j.micpath.2025.107625_bib143","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.4161\/hv.21616","article-title":"HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia","volume":"8","author":"Goldstein","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"issue":"3","key":"10.1016\/j.micpath.2025.107625_bib144","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/vaccines7030105","article-title":"Peptide-based vaccination for antibody responses against HIV","volume":"7","author":"Combadi\u00e8re","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.micpath.2025.107625_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-017-2316-x","article-title":"The therapeutic HIV Env C5\/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I\/II clinical study","volume":"17","author":"Brekke","year":"2017","journal-title":"BMC Infect. Dis."},{"issue":"48","key":"10.1016\/j.micpath.2025.107625_bib146","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1016\/j.vaccine.2013.09.057","article-title":"Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial","volume":"31","author":"Boffito","year":"2013","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.micpath.2025.107625_bib147","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/cid\/cir334","article-title":"Clinical applications of DNA vaccines: current progress","volume":"53","author":"Ferraro","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.micpath.2025.107625_bib148","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1517\/14712598.7.10.1563","article-title":"The potential of topical DNA vaccines adjuvanted by cytokines","volume":"7","author":"Lisziewicz","year":"2007","journal-title":"Expet Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.micpath.2025.107625_bib149","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAI.0000000000000830","article-title":"The safety and immunogenicity of an interleukin-12\u2013enhanced multiantigen DNA vaccine delivered by electroporation for the treatment of HIV-1 infection","volume":"71","author":"Jacobson","year":"2016","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"issue":"7","key":"10.1016\/j.micpath.2025.107625_bib150","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1080\/21645515.2018.1448328","article-title":"Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection","volume":"14","author":"Munson","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"issue":"3","key":"10.1016\/j.micpath.2025.107625_bib151","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.micpath.2025.107625_bib152","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/mSphere.00415-17","article-title":"Novel concepts for HIV vaccine vector design","volume":"2","author":"Alayo","year":"2017","journal-title":"mSphere"},{"issue":"18","key":"10.1016\/j.micpath.2025.107625_bib153","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1097\/QAD.0b013e32834cdaba","article-title":"Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir","volume":"25","author":"Persaud","year":"2011","journal-title":"AIDS"},{"issue":"24","key":"10.1016\/j.micpath.2025.107625_bib154","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.2217\/nnm.15.160","article-title":"The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials","volume":"10","author":"Roy","year":"2015","journal-title":"Nanomedicine"},{"issue":"10","key":"10.1016\/j.micpath.2025.107625_bib155","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1586\/erv.11.118","article-title":"DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV\/AIDS","volume":"10","author":"Lori","year":"2011","journal-title":"Expet Rev. Vaccine"},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib156","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/0973-029X.110741","article-title":"Human immunodeficiency virus vaccine an update","volume":"17","author":"Beena","year":"2013","journal-title":"J. Oral Maxillofac. Pathol."},{"issue":"4","key":"10.1016\/j.micpath.2025.107625_bib157","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1080\/21645515.2015.1011974","article-title":"Recent developments in clinical trial designs for HIV vaccine research","volume":"11","author":"Richert","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"issue":"5","key":"10.1016\/j.micpath.2025.107625_bib158","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/21645515.2016.1276138","article-title":"Progress in HIV vaccine development","volume":"13","author":"Hsu","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.micpath.2025.107625_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25793","article-title":"Current approaches to HIV vaccine development: a narrative review","volume":"24","author":"Kim","year":"2021","journal-title":"J. Int. AIDS Soc."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jiph.2014.08.003","article-title":"Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV\/AIDS: a systematic review","volume":"8","author":"Cobucci","year":"2015","journal-title":"J. Infect. Public Health."},{"issue":"1","key":"10.1016\/j.micpath.2025.107625_bib161","first-page":"218","article-title":"Emerging need to use phytopharmaceuticals in the treatment of HIV","volume":"6","author":"Narayan","year":"2013","journal-title":"J. Pharm. Res."},{"key":"10.1016\/j.micpath.2025.107625_bib162","first-page":"10","article-title":"Potential of nanocarriers in antigen delivery: the path to successful vaccine delivery","volume":"1","author":"Prabhu","year":"2014","journal-title":"Nanocarriers"}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088240102500350X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088240102500350X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:09:03Z","timestamp":1769202543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088240102500350X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":162,"alternative-id":["S088240102500350X"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2025.107625","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing nanotechnology in HIV therapy: Exploring molecular pathogenesis and treatment strategies with special reference to chemotherapy and immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2025.107625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107625"}}